ReviewRespiratory research2006
Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?
Review in Respiratory research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Reply to the Letter to the Editor: Expanding the clinical relevance of dynamic perfusion area-detector CT-recommendations for broader applicability.European radiology · 2025Article
- Development of novel technology for the visualization and quantitation of angiogenesis and the alveolar-capillary network in a mouse model of fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches.International journal of molecular sciences · 2022Review
- PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.Respiratory research · 2022Article
- Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: potential role of endothelial-to-mesenchymal transition.ERJ open research · 2022Article
- Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2021Article
- Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease.Internal medicine (Tokyo, Japan) · 2020Article
- Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.EBioMedicine · 2019Article
- VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease.International journal of molecular sciences · 2018Review
- Transforming growth factor-beta 1 in humidifier disinfectant-associated children's interstitial lung disease.Pediatric pulmonology · 2016Article
- Altered miRNA expression in pulmonary sarcoidosis.BMC medical genetics · 2016Article
- Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis.QJM : monthly journal of the Association of Physicians · 2014Review
- A review of current and novel therapies for idiopathic pulmonary fibrosis.Journal of thoracic disease · 2013Article
- Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients.BMC research notes · 2012Article
- Peripheral blood biomarkers in idiopathic pulmonary fibrosis.Translational research : the journal of laboratory and clinical medicine · 2012Review
- Spontaneous lung dysfunction and fibrosis in mice lacking connexin 40 and endothelial cell connexin 43.The American journal of pathology · 2011Article
- Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function.European journal of medical research · 2010Article
- Article
- Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes.European journal of medical research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past ten years parallels have been drawn between the biology of cancer and pulmonary fibrosis. The unremitting recruitment and maintenance of the altered fibroblast phenotype with generation and proliferation of immortal myofibroblasts is reminiscent with the transformation of cancer cells. A hallmark of tumorigenesis is the production of new blood vessels to facilitate tumor growth and mediate organ-specific metastases. On the other hand several chronic fibroproliferative disorders including fibrotic lung diseases are associated with aberrant angiogenesis. Angiogenesis, the process of new blood vessel formation is under strict regulation determined by a dual, yet opposing balance of angiogenic and angiostatic factors that promote or inhibit neovascularization, respectively. While numerous studies have examined so far the interplay between aberrant vascular and matrix remodeling the relative role of angiogenesis in the initiation and/or progression of the fibrotic cascade still remains elusive and controversial. The current article reviews data concerning the pathogenetic role of angiogenesis in the most prevalent and studied members of ILD disease-group such as IIPs and sarcoidosis, presents some of the future perspectives and formulates questions for potential further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.